Aclaris Therapeutics, Inc. Forecast, price target & analysts
Aclaris Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Aclaris Therapeutics, Inc. Classifications & Recommendation:
Aclaris Therapeutics, Inc. Price Target
| Target Price | $7.14 |
| Price | $2.27 |
| Potential |
214.54%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Aclaris Therapeutics, Inc. 2026 .
The average Aclaris Therapeutics, Inc. target price is $7.14.
This is
214.54%
register free of charge
$16.80
640.09%
register free of charge
$2.02
11.01%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend Aclaris Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Aclaris Therapeutics, Inc. stock has an average upside potential 2026 of
214.54%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 18.72 | 5.96 |
| 40.10% | 68.17% | |
| EBITDA Margin | -275.21% | -1,316.76% |
| 2.87% | 378.45% | |
| Net Margin | -705.50% | -985.25% |
| 149.17% | 39.65% |
10 Analysts have issued a sales forecast Aclaris Therapeutics, Inc. 2025 . The average Aclaris Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Aclaris Therapeutics, Inc. EBITDA forecast 2025. The average Aclaris Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Aclaris Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Aclaris Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.71 | -0.54 |
| 34.65% | 68.42% | |
| P/E | negative | |
| EV/Sales | 24.52 |
10 Analysts have issued a Aclaris Therapeutics, Inc. forecast for earnings per share. The average Aclaris Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Aclaris Therapeutics, Inc....
Current Aclaris Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 25 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | May 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 25 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
May 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 18 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 07 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
